Covered recipient · General Payments record
MARCELO VAILATI NEGRAO
Allopathic & Osteopathic Physicians Internal Medicine Medical Oncology
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2022 · Entire year
$149.43
1 record · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2022 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $149.43 | 1 |
By paying entity
PY2022 · entire year · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Genentech, Inc. | $149.43 | 1 |
Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
MARCELO VAILATI NEGRAO
NPI 1376070300 · CMS profile ID 4003636
Allopathic & Osteopathic Physicians / Internal Medicine / Medical Oncology
HOUSTON, TX
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1376070300?year=2022&recipient=provider#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- MARCELO VAILATI NEGRAO, NPI 1376070300, CMS profile ID 4003636. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1376070300?year=2022&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
- APA 7
- IndustryPayments. (2026). MARCELO VAILATI NEGRAO, NPI 1376070300, CMS profile ID 4003636. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1376070300?year=2022&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
- Bluebook
- MARCELO VAILATI NEGRAO, NPI 1376070300, CMS profile ID 4003636, IndustryPayments, General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c. https://industrypayments.org/provider/npi-1376070300?year=2022&recipient=provider#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2022
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2022 · Physicians and non-physician practitioners · CMS publication 2026-06-30
1 matching record · $149.43 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 1–1 of 1.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| Genentech, Inc. | $149.43 | 06/03/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 950660457 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2022, 2023, 2024, 2025
Source files and profile matching
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Recipient | $6,846.52 | 6 |
| PY2025 | Principal investigator | $2,059,899.37 | 28 |
| PY2024 | Recipient | $4,470.00 | 3 |
| PY2024 | Principal investigator | $3,036,066.58 | 21 |
| PY2023 | Recipient | $3,547.90 | 2 |
| PY2023 | Principal investigator | $2,419,476.23 | 22 |
| PY2022 | Recipient | $353.00 | 1 |
| PY2022 | Principal investigator | $864,167.42 | 17 |
| PY2021 | Principal investigator | $1,014,815.80 | 49 |
| PY2020 | Principal investigator | $1,405,196.16 | 1 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
34 records in PY2025
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | Genentech, Inc. | $50,420.00 | 12/05/2025 | Covered Recipient Teaching Hospital Ut Md Anderson Cancer Center | NAUTIKA1 previously LCMC4 | No dispute reported | 06/30/2026 | 1211563195 |
| Principal investigator 1 | Genentech, Inc. | $11,280.00 | 11/12/2025 | Covered Recipient Teaching Hospital Ut Md Anderson Cancer Center | NAUTIKA1 previously LCMC4 | No dispute reported | 06/30/2026 | 1211563191 |
| Recipient | PFIZER INC. | $3,200.00 | 11/03/2025 | Covered Recipient Physician | SIGVOTATUG VEDOTIN CLINICAL PUBLICATION PROGRAM | No dispute reported | 06/30/2026 | 1228804536 |
| Principal investigator 1 | Genentech, Inc. | $79,642.00 | 10/30/2025 | Covered Recipient Teaching Hospital Ut Md Anderson Cancer Center | NAUTIKA1 previously LCMC4 | No dispute reported | 06/30/2026 | 1211563182 |
| Principal investigator 1 | Genentech, Inc. | $14,315.00 | 10/24/2025 | Covered Recipient Teaching Hospital Ut Md Anderson Cancer Center | NAUTIKA1 previously LCMC4 | No dispute reported | 06/30/2026 | 1211563178 |
| Recipient | F. Hoffmann-La Roche AG | $278.26 | 10/23/2025 | Covered Recipient Physician | NAUTIKA1 previously LCMC4 | No dispute reported | 06/30/2026 | 1211537519 |
| Recipient | F. Hoffmann-La Roche AG | $278.26 | 10/23/2025 | Covered Recipient Physician | NAUTIKA1 previously LCMC4 | No dispute reported | 06/30/2026 | 1211537522 |
| Principal investigator 1 | Genentech, Inc. | $1,688.00 | 10/23/2025 | Covered Recipient Teaching Hospital Ut Md Anderson Cancer Center | NAUTIKA1 previously LCMC4 | No dispute reported | 06/30/2026 | 1211563187 |
| Recipient | PFIZER INC. | $940.00 | 10/19/2025 | Covered Recipient Physician | BINIMETINIB CLINICAL PUBLICATION PROGRAM | No dispute reported | 06/30/2026 | 1228804531 |
| Principal investigator 1 | PFIZER INC. | $23,590.88 | 09/16/2025 | Covered Recipient Teaching Hospital Ut Md Anderson Cancer Center | AN OPENLABEL RANDOMIZED CONTROLLED PHASE 3 STUDY OF SIGVOTATUG VEDOTIN IN COMBINATION WITH PEMBROLIZUMAB COMPARED WITH PEMBROLIZUMAB MONOTHERAPY AS FIRSTLINE TREATMENT IN PARTICIPANTS WITH PDL1 HIGH 50 OF TUMOR CELLS EXPRESSING PDL1 LOCALLY ADVANCED UNRESECTABLE OR METASTATIC NONSMALL CELL LUNG CANCER BE6A LUNG02 | No dispute reported | 06/30/2026 | 1228712224 |
| Principal investigator 1 | PFIZER INC. | $47,181.76 | 09/16/2025 | Covered Recipient Teaching Hospital Ut Md Anderson Cancer Center | AN OPENLABEL RANDOMIZED CONTROLLED PHASE 3 STUDY OF SIGVOTATUG VEDOTIN IN COMBINATION WITH PEMBROLIZUMAB COMPARED WITH PEMBROLIZUMAB MONOTHERAPY AS FIRSTLINE TREATMENT IN PARTICIPANTS WITH PDL1 HIGH 50 OF TUMOR CELLS EXPRESSING PDL1 LOCALLY ADVANCED UNRESECTABLE OR METASTATIC NONSMALL CELL LUNG CANCER BE6A LUNG02 | No dispute reported | 06/30/2026 | 1228712422 |
| Principal investigator 1 | Eli Lilly and Company | $566.00 | 08/26/2025 | Non-covered Recipient Entity NORTHWEST CLINICAL RESEARCH CENTER | A PHASE 3, MULTICENTER, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY ASSESSING THE EFFICACY AND SAFETY OF OLOMORASIB IN COMBINATION WITH STANDARD OF CARE IMMUNOTHERAPY IN PARTICIPANTS WITH RESECTED OR UNRESECTABLE KRAS G12C-MUTANT, NON-SMALL CELL LUNG CANCER - SUNRAY-02 | No dispute reported | 06/30/2026 | 1187886082 |
| Recipient | PFIZER INC. | $1,820.00 | 08/22/2025 | Covered Recipient Physician | DACOMITINIB CLINICAL PUBLICATION PROGRAM | No dispute reported | 06/30/2026 | 1228804523 |
| Principal investigator 1 | Genentech, Inc. | $16,498.00 | 07/04/2025 | Covered Recipient Teaching Hospital Ut Md Anderson Cancer Center | NAUTIKA1 previously LCMC4 | No dispute reported | 06/30/2026 | 1211563165 |
| Principal investigator 1 | Genentech, Inc. | $2,669.00 | 05/29/2025 | Covered Recipient Teaching Hospital Ut Md Anderson Cancer Center | NAUTIKA1 previously LCMC4 | No dispute reported | 06/30/2026 | 1211563150 |
| Principal investigator 1 | Genentech, Inc. | $13,921.00 | 05/23/2025 | Covered Recipient Teaching Hospital Ut Md Anderson Cancer Center | NAUTIKA1 previously LCMC4 | No dispute reported | 06/30/2026 | 1211563161 |
| Principal investigator 1 | Genentech, Inc. | $24,500.00 | 05/21/2025 | Covered Recipient Teaching Hospital Ut Md Anderson Cancer Center | NAUTIKA1 previously LCMC4 | No dispute reported | 06/30/2026 | 1211563157 |
| Recipient | PFIZER INC. | $330.00 | 05/13/2025 | Covered Recipient Physician | ENCORAFENIB CLINICAL PUBLICATION PROGRAM | No dispute reported | 06/30/2026 | 1228837710 |
| Principal investigator 1 | Mirati Therapeutics, Inc. | $35,754.92 | 05/07/2025 | Covered Recipient Teaching Hospital Ut Md Anderson Cancer Center | A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients With Advanced Solid Tumors With KRAS G12C Mutation KRYSTAL-1 | No dispute reported | 06/30/2026 | 1236529892 |
| Principal investigator 1 | Genentech, Inc. | $7,918.00 | 04/11/2025 | Covered Recipient Teaching Hospital Ut Md Anderson Cancer Center | NAUTIKA1 previously LCMC4 | No dispute reported | 06/30/2026 | 1211563154 |
| Principal investigator 1 | ARRAY BIOPHARMA INC | $12,557.50 | 03/26/2025 | Covered Recipient Teaching Hospital Ut Md Anderson Cancer Center | A PHASE 2 OPENLABEL STUDY OF ENCORAFENIB BINIMETINIB IN PATIENTS WITH BRAFV600MUTANT NONSMALL CELL LUNG CANCER | No dispute reported | 06/30/2026 | 1228843585 |
| Principal investigator 1 | ARRAY BIOPHARMA INC | $8,301.75 | 03/26/2025 | Covered Recipient Teaching Hospital Ut Md Anderson Cancer Center | A PHASE 2 OPENLABEL STUDY OF ENCORAFENIB BINIMETINIB IN PATIENTS WITH BRAFV600MUTANT NONSMALL CELL LUNG CANCER | No dispute reported | 06/30/2026 | 1228845590 |
| Principal investigator 1 | ARRAY BIOPHARMA INC | $1,406.25 | 03/26/2025 | Covered Recipient Teaching Hospital Ut Md Anderson Cancer Center | A PHASE 2 OPENLABEL STUDY OF ENCORAFENIB BINIMETINIB IN PATIENTS WITH BRAFV600MUTANT NONSMALL CELL LUNG CANCER | No dispute reported | 06/30/2026 | 1228846605 |
| Principal investigator 1 | ARRAY BIOPHARMA INC | $8,764.47 | 03/19/2025 | Covered Recipient Teaching Hospital Ut Md Anderson Cancer Center | A PHASE 2 OPENLABEL STUDY OF ENCORAFENIB BINIMETINIB IN PATIENTS WITH BRAFV600MUTANT NONSMALL CELL LUNG CANCER | No dispute reported | 06/30/2026 | 1228846617 |
| Principal investigator 1 | Mirati Therapeutics, Inc. | $56,004.90 | 02/26/2025 | Covered Recipient Teaching Hospital Ut Md Anderson Cancer Center | Phase 1/2 Study of MRTX849 in Patients With Cancer Having a KRAS G12C Mutation KRYSTAL-1 | No dispute reported | 06/30/2026 | 1236529888 |
| Principal investigator 1 | ARRAY BIOPHARMA INC | $1,000.00 | 02/07/2025 | Covered Recipient Teaching Hospital Ut Md Anderson Cancer Center | A PHASE 2 OPENLABEL STUDY OF ENCORAFENIB BINIMETINIB IN PATIENTS WITH BRAFV600MUTANT NONSMALL CELL LUNG CANCER | No dispute reported | 06/30/2026 | 1228845606 |
| Principal investigator 1 | ARRAY BIOPHARMA INC | $16,983.00 | 02/07/2025 | Covered Recipient Teaching Hospital Ut Md Anderson Cancer Center | A PHASE 2 OPENLABEL STUDY OF ENCORAFENIB BINIMETINIB IN PATIENTS WITH BRAFV600MUTANT NONSMALL CELL LUNG CANCER | No dispute reported | 06/30/2026 | 1228846609 |
| Principal investigator 1 | ARRAY BIOPHARMA INC | $7,500.00 | 02/07/2025 | Covered Recipient Teaching Hospital Ut Md Anderson Cancer Center | A PHASE 2 OPENLABEL STUDY OF ENCORAFENIB BINIMETINIB IN PATIENTS WITH BRAFV600MUTANT NONSMALL CELL LUNG CANCER | No dispute reported | 06/30/2026 | 1228846661 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $43,159.91 | 02/04/2025 | Covered Recipient Teaching Hospital Ut Md Anderson Cancer Center | A phase Ib/II open-label, multi-center dose escalation study of JDQ443 in patients with advanced solid tumors harboring the KRAS G12C mutation | No dispute reported | 06/30/2026 | 1190294331 |
| Principal investigator 1 | Eli Lilly and Company | $5,831.54 | 01/27/2025 | Covered Recipient Teaching Hospital UT MD ANDERSON CANCER CENTER | SUNRAY-01 A GLOBAL PIVOTAL STUDY IN PARTICIPANTS WITH KRAS G12C-MUTANT LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER COMPARING FIRST LINE TREATMENT OF LY3537982 AND PEMBROLIZUMAB VS PLACEBO AND PEMBROLIZUMAB IN THOSE WITH PD L1 EXPRESSION 50% OR LY3537982 AND PEMBROLIZUMAB PEMETREXED PLATINUM VS PLACEBO AND PEMBROLIZUMAB PEMETREXED PLATINUM REGARDLESS OF PD-L1 EXPRESSION | No dispute reported | 06/30/2026 | 1187875031 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $172,376.56 | 01/23/2025 | Covered Recipient Teaching Hospital Ut Md Anderson Cancer Center | A Phase 1/2 Trial of MRTX849 in Combination with ABI-009 in Patients with Advanced Solid Tumors and Non-Small Cell Lung Cancer with KRAS G12C Mutation | No dispute reported | 06/30/2026 | 1235999495 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $960,301.93 | 01/07/2025 | Covered Recipient Teaching Hospital Ut Md Anderson Cancer Center | A Phase II trial of PARP inhibition, radiation, and immunotherapy in patients with Extensive-Stage Small Cell Lung Cancer (ES-SCLC) - PRIO Trial | No dispute reported | 06/30/2026 | 1185538012 |
| Principal investigator 1 | Eli Lilly and Company | $434,857.00 | 01/07/2025 | Covered Recipient Teaching Hospital UT MD ANDERSON CANCER CENTER | SUNRAY-01 A GLOBAL PIVOTAL STUDY IN PARTICIPANTS WITH KRAS G12C-MUTANT LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER COMPARING FIRST LINE TREATMENT OF LY3537982 AND PEMBROLIZUMAB VS PLACEBO AND PEMBROLIZUMAB IN THOSE WITH PD L1 EXPRESSION 50% OR LY3537982 AND PEMBROLIZUMAB PEMETREXED PLATINUM VS PLACEBO AND PEMBROLIZUMAB PEMETREXED PLATINUM REGARDLESS OF PD-L1 EXPRESSION | No dispute reported | 06/30/2026 | 1187873501 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $910.00 | 01/01/2025 | Non-covered Recipient Entity UT MD ANDERSON CANCER CENTER CLINICAL CANCER PREVENTION | A phase Ib/II open-label, multi-center dose escalation study of JDQ443 in patients with advanced solid tumors harboring the KRAS G12C mutation | No dispute reported | 06/30/2026 | 1190308980 |